Notes from last week’s cnbc interview. Still can’t find latest concall.
- Seeing pressure in pharma and api industry. 58% revenue is derived from there. The situation should become better by next quarter depending on gas prices/raw material price normalisation(russian/ukraine war and china slowdown)
- Margins might stay around 22%
- Still targeting 2400Cr revenues this year. This might indicate 1 more quarter of muted growth.
- Agro industry revenue share is around 20-25% and is doing well
- Balaji Specialty Chemical IPO work is still in progress
- New methylamine plant will be functional by Q1FY24 and butylamine plant is pending government clearance.
- Not slowing down on setting up new plants as they expect pharma industry to bounce back.